Your session is about to expire
← Back to Search
Aerobic Exercise + Cognitive Training for Mild Cognitive Impairment
N/A
Recruiting
Research Sponsored by Arizona State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Age 65 years and older
Stable on drugs affecting cognitive and psychological status
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline to 3, 6, 12, and 18 months
Awards & highlights
Study Summary
This trial is testing whether a cognitive intervention can improve cognition and related brain mechanisms in older adults with aMCI.
Who is the study for?
This trial is for English-speaking adults aged 65 or older with mild cognitive impairment (MCI) who can legally consent and are living in the community. They must be able to safely exercise, have good vision, and their medication affecting cognition should be stable. People with unassessed new symptoms, enrolled in other cognitive studies, abnormal MRI results, certain heart rates or conditions that make exercise unsafe cannot join.Check my eligibility
What is being tested?
The ACT Trial investigates if a combination of aerobic exercise and cognitive training improves brain function in older adults with MCI. It compares four approaches: combined physical and mental exercises (ACT), cycling only, mental exercises only, and stretching with stimulating activities to see which has the best effect on cognition.See study design
What are the potential side effects?
Potential side effects may include typical risks associated with moderate physical activity such as muscle soreness or strain. Cognitive training might cause temporary mental fatigue. The study will monitor participants closely for any adverse reactions.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 65 years old or older.
Select...
My mental health medication has not changed recently.
Select...
I have been diagnosed with mild cognitive impairment.
Select...
I can see well enough for daily activities.
Select...
I am able to understand and agree to the study's procedures and risks.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ change from baseline to 3, 6, 12, and 18 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline to 3, 6, 12, and 18 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Cognition
Secondary outcome measures
AD-signature cortical thickness
Aerobic fitness
Conversion to Alzheimer's diseae
+1 moreSide effects data
From 2020 Phase 3 trial • 310 Patients • NCT0335566429%
anaemia
21%
thrombocytopenia
15%
aspartate transferase (AST)
14%
abdominal pain
13%
alanyl transferase (ALT)
13%
headache
11%
diarrhoea
10%
fatigue
10%
dizziness
8%
sleep disturbance
8%
vomiting
7%
nausea
6%
creatinine
6%
loss of appetite
5%
alkaline phosphatase (ALP)
3%
blurred vision
3%
itching
1%
gastritis
1%
severe malaria
1%
Transaminitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24
Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24
Trial Design
4Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: ACTExperimental Treatment1 Intervention
Moderate-intensity cycling followed by computerized cognitive training, 3 times a week for 6 months, supervised by a specialist
Group II: Cycling OnlyActive Control1 Intervention
Moderate-intensity cycling, 3 times a week for 6 months, supervised by an exercise specialist
Group III: Cognitive Training OnlyActive Control1 Intervention
Computerized cognitive training, 3 times a week for 6 months, supervised by a specialist
Group IV: Stretching and Mental Stimulation ActivitiesPlacebo Group1 Intervention
Stretching and mental stimulation activities, 3 times a week for 6 months, supervised by a specialist
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ACT
2017
Completed Phase 3
~5400
Find a Location
Who is running the clinical trial?
Arizona State UniversityLead Sponsor
282 Previous Clinical Trials
108,846 Total Patients Enrolled
University of RochesterOTHER
834 Previous Clinical Trials
518,021 Total Patients Enrolled
Mayo ClinicOTHER
3,190 Previous Clinical Trials
3,757,969 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am 65 years old or older.You live in your own home or apartment, not in a hospital or nursing facility.My mental health medication has not changed recently.I have new symptoms or health issues that haven't been checked by a doctor.I have been diagnosed with mild cognitive impairment.I can see well enough for daily activities.You have had significant mental health issues like dementia, head trauma, bipolar disorder, schizophrenia, depression, or substance addiction in the past 5 years that may affect your memory and thinking abilities.I am able to understand and agree to the study's procedures and risks.You have a low score (less than 5) on a test that measures symptoms of depression in older adults.
Research Study Groups:
This trial has the following groups:- Group 1: Cycling Only
- Group 2: Cognitive Training Only
- Group 3: ACT
- Group 4: Stretching and Mental Stimulation Activities
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Who else is applying?
What site did they apply to?
University of Minnesota
What portion of applicants met pre-screening criteria?
Did not meet criteria
Share this study with friends
Copy Link
Messenger